Announced Fri, 3 Jul · 15:06 IST
Routine compliance certificate for Q1 FY27 share dematerialisation filing
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+13.7%1-day move
₹14.27
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+13.7+25.1+28.6+24.5+23.0+15.8+15.6———
Up moveDown movePending
AI summary
Norris Medicines Ltd submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The company's Registrar and Transfer Agent, Purva Sharegistry India, confirmed that 15 share certificates totalling about 1,740 shares received for dematerialisation were processed and confirmed to depositories within the prescribed timelines. Signed by Director Praveenchand Bafna.
Likely market impact
Standard procedural compliance filing with no material impact on business or shareholders.